首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: A report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015
【24h】

Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: A report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015

机译:日本急性肝衰竭和迟发性肝衰竭病因分类的修订标准:日本顽固性肝胆疾病研究小组于2015年发表的报告

获取原文
获取原文并翻译 | 示例
       

摘要

In 2011, the Intractable Liver Diseases Study Group of Japan, established novel diagnostic criteria for "acute liver failure", and published the classification criteria for the etiologies of acute liver failure and late-onset hepatic failure (LOHF) in 2013. According to this classification, HBV carriers showing acute hepatitis exacerbation were divided into 3 subgroups; asymptomatic or inactive HBV carriers without drug exposure, asymptomatic or inactive HBV carriers developing HBV reactivation during and after immunosuppressive therapies and/or antineoplastic chemotherapies and those with previously resolved HBV infection showing iatrogenic HBV reactivation. In an annual nationwide survey in 2013, however, a patient with previously resolved HBV infection was enrolled, in whom LOHF developed as a result of HBV reactivation despite in the absence of immunosuppressive therapies and/or antineoplastic chemotherapies. Thus, the study group revised the classification criteria in 2015; HBV carriers developing acute hepatitis exacerbation were classified into asymptomatic or inactive HBV carriers and patients with previously resolved HBV infection, and both groups were further sub-classified into those receiving immunosuppressive therapies and/or antineoplastic chemotherapies and those without such drugs exposure.
机译:2011年,日本难治性肝病研究小组建立了“急性肝衰竭”的新诊断标准,并于2013年发布了急性肝衰竭和迟发性肝衰竭(LOHF)病因的分类标准。分类将显示急性肝炎加重的HBV携带者分为3个亚组。无症状或无活性的HBV携带者,无药物暴露,无症状或无活性的HBV携带者在免疫抑制治疗和/或抗肿瘤化学疗法期间和之后以及先前已解决的HBV感染者中出现医源性HBV激活而发展为HBV激活。然而,在2013年的年度全国性调查中,招募了一名先前已解决HBV感染的患者,尽管缺乏免疫抑制疗法和/或抗肿瘤化学疗法,但由于HBV激活导致LOHF发生。因此,研究小组在2015年修订了分类标准;发生急性肝炎急性发作的HBV携带者分为无症状或无活动性HBV携带者以及先前已解决HBV感染的患者,两组又进一步分为接受免疫抑制疗法和/或抗肿瘤化学疗法的患者以及未接触此类药物的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号